Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer.
Abstract:#4117
Background: Motesanib is a novel oral angiogenesis inhibitor designed to selectively target the tyrosine kinase activity of VEGF 1, 2 and 3; PDGF and Kit receptors. Here we report safety, preliminary efficacy and pharmacokinetics (PK) from an ongoing phase 1b dose-finding study of motesanib plus either paclitaxel (P) or docetaxel (D) in patients (pts) with advanced breast cancer.
 Methods: Eligible pts with ECOG 0 or 1 and ≤1 prior chemotherapy regimen for metastatic breast canc… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.